Solid Tumor, Adult Clinical Trials in Fairfax, Virginia
12 recruitingFairfax, Virginia
Showing 1–12 of 12 trials
Recruiting
Phase 1
First In Human Study of CX-2051 in Advanced Solid Tumors
Solid Tumor, Adult
CytomX Therapeutics160 enrolled7 locationsNCT06265688
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Colorectal, CancerNon-small Cell Lung CancerPancreatic Ductal Adenocarcinoma+2 more
Verastem, Inc.295 enrolled14 locationsNCT07020221
Recruiting
Phase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
MelanomaNSCLCSolid Tumor, Adult+6 more
Nested Therapeutics, Inc230 enrolled23 locationsNCT06326411
Recruiting
Phase 1Phase 2
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Colorectal, CancerPancreatic CancerMetastatic Solid Tumor+5 more
Frontier Medicines Corporation403 enrolled26 locationsNCT06244771
Recruiting
Phase 1
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Non-small Cell Lung CancerHER2Advanced Solid Tumor, Adult+3 more
Cogent Biosciences, Inc.100 enrolled6 locationsNCT07361562
Recruiting
Phase 1
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Solid Tumor, Adult
Kumquat Biosciences Inc.100 enrolled35 locationsNCT06507306
Recruiting
Phase 1Phase 2
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Solid Tumor, Adult
Corbus Pharmaceuticals Inc.348 enrolled41 locationsNCT06265727
Recruiting
Phase 1
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Endometrial CancerMetastatic Solid TumorSolid Tumor, Adult+4 more
Sairopa B.V.130 enrolled7 locationsNCT05856981
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1Phase 2
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Non-small Cell Lung CancerSolid Tumor, AdultCutaneous Melanoma+4 more
GV20 Therapeutics365 enrolled13 locationsNCT05669430
Recruiting
Phase 1Phase 2
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Solid Tumor, Adult
Effector Therapeutics30 enrolled14 locationsNCT04092673